Plain-English translation of NCT04572451 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of three treatments for people with advanced solid tumors and melanoma: focused radiation therapy (called SBRT), an immunotherapy drug called , and an experimental medication called . Researchers want to see if using all three together is safe and whether it can help fight cancer that has spread to multiple places in the body.
Many people with advanced cancer don't respond well enough to current treatments, especially melanoma patients whose cancer has stopped responding to standard immunotherapy. This trial is testing whether combining radiation with two different types of immunotherapy might work better by helping the immune system attack the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would receive radiation therapy targeted at your tumors, along with regular infusions of two immunotherapy medications every 2–4 weeks. The study has two phases: the first focuses on safety and finding the right doses in various cancer patients, and the second specifically tests effectiveness in melanoma patients whose cancer didn't respond to prior immunotherapy. You would have regular visits for scans, blood tests, and check-ins to monitor how you're responding and watch for side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States